LAS VEGAS—Treatment of 25-hydroxyvitamin D (25(OH)D) deficiency with ergocalciferol in patients with moderate chronic kidney disease (CKD) is associated with a significant reduction in the risk of cardiovascular (CV) events, new data presented at the National Kidney Foundation’s Spring Clinical Meetings suggest.
LAS VEGAS—Switching anemic pre-dialysis chronic kidney disease (CKD) from darbepoetin to epoetin is associated with longer dosing intervals and lower drug costs, and hemoglobin levels are maintained in the recommended target range, according to a study presented at the National Kidney Foundation’s Spring Clinical Meetings.
LAS VEGAS—Women with an estimated glomerular filtration rate (eGFR) of 60 mL/min/1.73 m2 or higher are at higher risk than men for experiencing radiocontrast-induced nephropathy (RCIN) following coronary angiography, investigators reported at the National Kidney Foundation’s Spring Clinical Meetings.
LAS VEGAS—Statin use by non-diabetic patients with end-stage renal disease may decrease paricalcitol use, researcher reported at the National Kidney Foundation’s Spring Clinical Meetings.
LAS VEGAS—Pulmonary hypertension is a strong predictor of the need for renal replacement therapy (RRT) after lung transplantation, according to new findings presented at the National Kidney Foundation’s Spring Clinical Meetings.
LAS VEGAS—Blood transfusions are common for non-dialysis chronic kidney disease (ND-CKD) patients with persistent anemia, according to a report presented at the National Kidney Foundation’s Spring Clinical Meetings.
LAS VEGAS—Even modest rises in serum potassium at critical care initiation is a significant predictor of all-cause mortality, according to findings presented here at the National Kidney Foundation’s Spring Clinical Meetings.
LAS VEGAS—Inpatient cost savings may offset the costs of patient adherence to cinacalcet therapy, according to study findings presented at the National Kidney Foundation’s Spring Clinical Meetings.
LAS VEGAS—Sustained low-efficiency daily dialysis (SLEDD) for intensive care unit (ICU) patients does not offer a survival advantage over intermittent hemodialysis (IHD), according to data reported at the National Kidney Foundation’s Spring Clinical Meetings.
LAS VEGAS—Replacing 25-hydroxyvitamin D (25(OH)D) in hemodialysis (HD) patients who are deficient in the vitamin does not result in a significant decrease in intact parathyroid hormone (iPTH) level, researchers reported at the National Kidney Foundation’s Spring Clinical Meetings.
Please login or register first to view this content.
